New drug cocktail aims to shrink melanoma before surgery
NCT ID NCT04207086
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the drugs for six weeks, then have surgery to check how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option to reduce or eliminate melanoma before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase (phase II) study with only 21 participants, so results may not apply broadly. The drugs can cause significant side effects, and the trial is not randomized, limiting comparisons.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
North Sydney, New South Wales, 2060, Australia